JP7767613B2 - 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用 - Google Patents

二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用

Info

Publication number
JP7767613B2
JP7767613B2 JP2024529137A JP2024529137A JP7767613B2 JP 7767613 B2 JP7767613 B2 JP 7767613B2 JP 2024529137 A JP2024529137 A JP 2024529137A JP 2024529137 A JP2024529137 A JP 2024529137A JP 7767613 B2 JP7767613 B2 JP 7767613B2
Authority
JP
Japan
Prior art keywords
mmol
compound
antibody
seq
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024529137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543508A (ja
JP2024543508A5 (cg-RX-API-DMAC10.html
Inventor
ジュー，イー
ワン，ウェイリィ
ユィ，ティエンズー
ジュー，グゥイリィ
ジャン，イィイィン
ジュオ，シー
ジャン，ヨン
リィ，ガァンロゥイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Systimmune Inc
Original Assignee
Systimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc filed Critical Systimmune Inc
Publication of JP2024543508A publication Critical patent/JP2024543508A/ja
Publication of JP2024543508A5 publication Critical patent/JP2024543508A5/ja
Priority to JP2025182282A priority Critical patent/JP2026035591A/ja
Application granted granted Critical
Publication of JP7767613B2 publication Critical patent/JP7767613B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024529137A 2021-11-15 2022-11-15 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用 Active JP7767613B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182282A JP2026035591A (ja) 2021-11-15 2025-10-29 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111351599.X 2021-11-15
CN202111351599 2021-11-15
PCT/CN2022/132027 WO2023083381A1 (zh) 2021-11-15 2022-11-15 双特异性抗体-喜树碱类药物偶联物及其医药用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182282A Division JP2026035591A (ja) 2021-11-15 2025-10-29 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用

Publications (3)

Publication Number Publication Date
JP2024543508A JP2024543508A (ja) 2024-11-21
JP2024543508A5 JP2024543508A5 (cg-RX-API-DMAC10.html) 2025-04-18
JP7767613B2 true JP7767613B2 (ja) 2025-11-11

Family

ID=86306961

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024529137A Active JP7767613B2 (ja) 2021-11-15 2022-11-15 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用
JP2025182282A Pending JP2026035591A (ja) 2021-11-15 2025-10-29 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182282A Pending JP2026035591A (ja) 2021-11-15 2025-10-29 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用

Country Status (14)

Country Link
US (3) US20250059296A1 (cg-RX-API-DMAC10.html)
EP (1) EP4434548A4 (cg-RX-API-DMAC10.html)
JP (2) JP7767613B2 (cg-RX-API-DMAC10.html)
KR (1) KR20240101682A9 (cg-RX-API-DMAC10.html)
CN (1) CN116120460B (cg-RX-API-DMAC10.html)
AU (1) AU2022386505A1 (cg-RX-API-DMAC10.html)
CA (1) CA3237844A1 (cg-RX-API-DMAC10.html)
CL (2) CL2024001450A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024006160A2 (cg-RX-API-DMAC10.html)
IL (1) IL312694A (cg-RX-API-DMAC10.html)
MX (1) MX2024005831A (cg-RX-API-DMAC10.html)
PE (1) PE20250759A1 (cg-RX-API-DMAC10.html)
TW (1) TW202434301A (cg-RX-API-DMAC10.html)
WO (1) WO2023083381A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023005152A2 (pt) * 2020-09-21 2023-04-25 Systimmune Inc Anticorpo biespecífico com especificidade intensificada (seba)
CN121568966A (zh) 2023-07-19 2026-02-24 映恩生物制药（苏州）有限公司 一种双特异性抗体、其药物偶联物及其用途
CN119504932A (zh) * 2023-08-23 2025-02-25 成都精西药业有限责任公司 一种连接子-药物的制备方法
KR20260096837A (ko) * 2023-10-18 2026-06-24 시스트이뮨, 인코포레이티드 항체 캄프토테신 약물 접합체를 이용한 종양 치료 방법 및 조성물
AU2024397535A1 (en) * 2023-12-13 2026-07-02 Systimmune, Inc. Anti-claudin18.2 antibody-camptothecin drug conjugate and pharmaceutical use thereof
CN120189525A (zh) * 2023-12-22 2025-06-24 信达生物制药(苏州)有限公司 靶向b7-h3和trop2的抗体-药物偶联物及其用途
WO2025131054A1 (en) * 2023-12-22 2025-06-26 Innovent Biologics (Suzhou) Co., Ltd. Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof
WO2025140662A1 (en) * 2023-12-29 2025-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/her3 antibodies and uses thereof
WO2026151284A1 (en) * 2025-01-10 2026-07-16 Aimed Bio Inc. Anti-cdcp1 antibody or antigen-binding fragment thereof, antibody-drug conjugate comprising the same, and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155976A1 (ja) 2014-04-10 2015-10-15 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲート
JP2018509175A (ja) 2014-12-22 2018-04-05 システィミューン， インク．Ｓｙｓｔｉｍｍｕｎｅ， Ｉｎｃ． 二重特異性四価抗体並びにその製作及び使用方法
CN111689980A (zh) 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2195622C (en) 1991-02-27 1999-08-17 Frank J. Urban Process for preparing trans-piperidine-2,5-dicarboxylates
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US20050142133A1 (en) 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
WO2009011285A1 (ja) 2007-07-13 2009-01-22 Taisho Pharmaceutical Co., Ltd. ヘテロアリールベンゼン化合物
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
KR20110044905A (ko) 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2010127284A2 (en) 2009-05-01 2010-11-04 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
CA2775573A1 (en) * 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
US8658175B2 (en) 2009-10-28 2014-02-25 Abbvie Biotherapeutics Inc. Anti-EGFR antibodies and their uses
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9051370B2 (en) 2010-08-10 2015-06-09 Glycotope Gmbh Humanized EGFR antibodies
UY33707A (es) 2010-11-04 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
CA2828099A1 (en) 2011-02-24 2012-08-30 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
EP2815765A1 (en) 2011-03-15 2014-12-24 Merrimack Pharmaceuticals, Inc. Overcoming resistance to ERBB pathway inhibitors
TW201333039A (zh) 2011-12-30 2013-08-16 Abbvie Inc 雙可變域免疫球蛋白及其用途
CA2866612C (en) 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
PE20150605A1 (es) 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
WO2013170263A2 (en) 2012-05-11 2013-11-14 Merrimack Pharmaceuticals, Inc. Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics
ES2690315T3 (es) 2012-06-15 2018-11-20 Mitsubishi Tanabe Pharma Corporation Compuestos de imidazol y triazol como inhibidores de DGAT-1
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
US20150239977A1 (en) 2012-09-27 2015-08-27 Massachusetts Institute Of Technology Cd20- and egfr-binding proteins with enhanced stability
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
MY186864A (en) 2013-03-12 2021-08-26 Biocon Ltd Fusion immunomodulatory proteins and methods for making same
EP2970485A1 (en) 2013-03-15 2016-01-20 Merck Patent GmbH Tetravalent bispecific antibodies
US10239951B2 (en) 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
JP6693872B2 (ja) 2013-07-25 2020-05-13 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
WO2015038984A2 (en) 2013-09-12 2015-03-19 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
EP3068892A4 (en) 2013-11-13 2017-05-31 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
SG10201902571VA (en) 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
EP3107557B1 (en) * 2014-02-17 2021-06-09 Seagen Inc. Hydrophilic antibody-drug conjugates
TWI871999B (zh) 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
WO2015189477A1 (en) 2014-06-13 2015-12-17 Tenboron Oy Conjugates comprising an anti-egfr1 antibody
CA2944085C (en) 2014-09-16 2018-04-10 Ease Charm Limited Anti-egfr antibody and uses of same
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
US12428483B2 (en) * 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
CN105820248A (zh) 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型抗egfr单克隆抗体的制备方法及应用
KR101770559B1 (ko) 2015-04-23 2017-08-24 신일제약주식회사 EGFR에 특이적으로 결합하는 Fab 단편
WO2016196682A1 (en) 2015-06-01 2016-12-08 Immunexcite, Inc. β-1,6-GLUCAN CETUXIMAB ANTIBODY CONJUGATES
CN107709356A (zh) 2015-06-26 2018-02-16 南加利福尼亚大学 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
CA2994969A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
EP3400248A4 (en) 2016-01-10 2019-09-04 Sorrento Therapeutics, Inc. IMPROVED SAFETY FOR THE TREATMENT OF CANCER WITH GLYCOSYLATED CHIMERIC ANTIBODY AGAINST EGFR
SG10202008909VA (en) 2016-03-24 2020-10-29 Bayer Pharma AG Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CN109563166B (zh) 2016-04-28 2022-12-20 拜奥穆尼克斯制药 靶向egfr和her2的双特异性抗体
CN116333130A (zh) 2016-05-24 2023-06-27 英斯梅德股份有限公司 抗体及其制备方法
WO2018026742A1 (en) 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
JPWO2018110515A1 (ja) 2016-12-12 2019-10-24 第一三共株式会社 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
GB201705686D0 (en) 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
CN108948195B (zh) 2017-05-23 2022-05-31 胡毅 一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
CN108948206B (zh) 2017-05-23 2022-08-23 赵磊 一种抗egfr/pd-1双靶向抗体、其制备方法及用途
US20200140547A1 (en) 2017-05-26 2020-05-07 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
WO2018228442A1 (en) 2017-06-14 2018-12-20 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof
AU2018288029B2 (en) 2017-06-19 2021-12-23 Systimmune, Inc. Antibody-drug conjugate having acidic self-stabilization junction
CN109306010B (zh) 2017-07-26 2022-07-19 石家庄以岭药业股份有限公司 表皮生长因子受体抗体及其用途
KR20210029298A (ko) 2017-08-16 2021-03-15 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16, 및 egfr, ccr4 또는 pd-l1에 결합하는 단백질
CN109106951A (zh) * 2017-08-18 2019-01-01 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
SG11202001514XA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
EP3677589B1 (en) 2017-08-31 2025-11-26 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
EP3457139B1 (en) 2017-09-19 2026-08-05 Promise Proteomics Antibody-like peptides for quantifying therapeutic antibodies
CN119264274A (zh) 2017-10-12 2025-01-07 免疫苏醒公司 Vegfr-抗体轻链融合蛋白
CN108220244A (zh) 2018-01-18 2018-06-29 东北农业大学 一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺
US10654944B2 (en) 2018-04-10 2020-05-19 Y-Biologics Inc. Cell engaging binding molecules
WO2019232323A1 (en) 2018-05-31 2019-12-05 Board Of Regents, The University Of Texas System Bi-specific antibodies and use thereof
MX2020014290A (es) 2018-06-22 2021-08-05 Cugene Inc Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
WO2020006486A1 (en) 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions and methods for antibody delivery
UA130338C2 (uk) 2018-09-26 2026-01-28 Джянгсу Хенгруй Медісін Ко., Лтд. Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування
JP7408646B2 (ja) 2018-09-30 2024-01-05 ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド 抗－ｂ７ｈ３抗体－エキサテカンアナログコンジュゲート及びその医薬用途
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
BR112021008486A2 (pt) 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
CN111196855B (zh) 2018-11-19 2022-11-15 三生国健药业（上海）股份有限公司 抗egfr/pd-1双特异性抗体
JP2022510218A (ja) 2018-11-30 2022-01-26 メモリアル スローン ケタリング キャンサー センター ヘテロ二量体四価特異性抗体およびこれらの使用
US12344646B2 (en) 2018-12-13 2025-07-01 Bang DING Antibody-TNF α fusion protein and its preparation and applications
EP3898681A2 (en) 2018-12-17 2021-10-27 Alligator Bioscience AB Polypeptides
KR102991359B1 (ko) 2018-12-28 2026-07-16 쿄와 기린 가부시키가이샤 TfR에 결합하는 이중 특이적 항체
AU2020288275A1 (en) 2019-06-06 2022-02-03 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Anti-B7-H4 antibody–drug conjugate and medicinal use thereof
WO2020259258A1 (zh) * 2019-06-28 2020-12-30 上海复旦张江生物医药股份有限公司 一种抗体偶联药物、其中间体、制备方法及应用
CN110256583B (zh) 2019-07-11 2022-05-20 中国科学院生物物理研究所 一种il-2突变体与抗体的融合蛋白及其应用
MX2022001027A (es) 2019-07-26 2022-04-18 Abl Bio Inc Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo.
CN110669132B (zh) 2019-08-19 2023-03-31 天津大学前沿技术研究院 一种提高IgG1抗体产量的方法
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
CA3151237A1 (en) 2019-09-19 2021-03-25 Ramesh Baliga Multimeric antibodies with enhanced selectivity for cells with high target density
AU2020402006A1 (en) 2019-12-12 2022-07-07 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
BR112022011632A2 (pt) 2019-12-16 2022-10-04 Jiangsu Hengrui Medicine Co Conjugado análogo de anticorpo exatecano anti-cea e uso farmacêutico do mesmo
US20230101735A1 (en) 2020-01-22 2023-03-30 Jiangsu Hengrui Medicine Co., Ltd. Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
WO2021173612A1 (en) 2020-02-26 2021-09-02 Sorrento Therapeutics, Inc. Activatable antigen binding proteins with universal masking moieties
CN113388631B (zh) 2020-03-12 2022-08-09 天津大学 一种高产IgG1的重组菌及构建方法
WO2021190480A1 (zh) 2020-03-24 2021-09-30 上海翰森生物医药科技有限公司 抗体-药物偶联物及其医药用途
WO2021190586A1 (zh) 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 B7h3抗体-依喜替康类似物偶联物及其医药用途
CN115103691B (zh) 2020-03-25 2025-01-24 苏州盛迪亚生物医药有限公司 一种含抗体药物偶联物的药物组合物及其用途
CA3175048A1 (en) 2020-03-25 2021-09-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for antibody medicament conjugate
MX2022011808A (es) 2020-03-25 2022-12-06 Jiangsu Hengrui Pharmaceuticals Co Ltd Conjugado de anticuerpo anti-psma-analogo de exatecan y uso medico del mismo.
WO2021190564A1 (zh) 2020-03-26 2021-09-30 上海翰森生物医药科技有限公司 抗体药物偶联物及其医药用途
US10994021B1 (en) 2020-04-11 2021-05-04 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Tetravalent antibody-drug conjugates and use thereof
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
CN113754771A (zh) 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pdl1×egfr的双特异性抗体
BR112022024930A2 (pt) * 2020-06-08 2022-12-27 Baili Bio Chengdu Pharmaceutical Co Ltd Fármaco de camptotecina possuindo unidade de conexão hidrofílica de alta estabilidade e conjugado do mesmo
CN111848806B (zh) 2020-06-18 2022-06-10 广东安普泽生物医药股份有限公司 Egfr-cd3双功能抗体及其应用
EP4190812A4 (en) 2020-07-27 2024-09-04 Tuojie Biotech (Shanghai) Co., Ltd. ANTI-CD79B ANTIBODY-DRUG CONJUGATE, ITS PREPARATION METHOD AND ITS PHARMACEUTICAL USE
NZ781239A (en) 2020-09-15 2024-11-29 Systimmune Inc A camptothecin drug and its antibody conjugate thereof
AU2021354827A1 (en) 2020-09-30 2023-06-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical composition
EP4227310A4 (en) 2020-10-12 2024-11-06 Sichuan Baili Pharmaceutical Co. Ltd. CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF
WO2022078259A1 (zh) * 2020-10-12 2022-04-21 四川百利药业有限责任公司 一种氘代的喜树碱衍生物及其抗体药物偶联物
CN116133694B (zh) 2020-10-14 2026-03-06 苏州盛迪亚生物医药有限公司 抗her3抗体和抗her3抗体药物偶联物及其医药用途
WO2022099762A1 (zh) 2020-11-12 2022-05-19 博瑞生物医药（苏州）股份有限公司 一种抗体偶联物中间体及其制备方法
CN114569739A (zh) 2020-12-01 2022-06-03 正大天晴药业集团股份有限公司 抗体药物偶联物
AU2022216696A1 (en) 2021-02-05 2023-08-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
CN114409562B (zh) 2021-02-08 2024-08-02 四川百利药业有限责任公司 一种ca4衍生物及其配体-药物偶联物
WO2022194257A1 (zh) 2021-03-17 2022-09-22 江苏恒瑞医药股份有限公司 一种喜树碱衍生物的制备方法
CN115192732B (zh) 2021-04-01 2025-02-18 成都百利多特生物药业有限责任公司 一种dna毒性二聚体化合物及其偶联物
TW202302649A (zh) 2021-04-26 2023-01-16 大陸商江蘇恆瑞醫藥股份有限公司 抗ｎｅｃｔｉｎ－４抗體和抗ｎｅｃｔｉｎ－４抗體－藥物偶聯物及其醫藥用途
CN113816969B (zh) 2021-04-30 2024-01-16 联宁（苏州）生物制药有限公司 依喜替康类化合物、其抗体药物偶联物及其应用
AU2022269073A1 (en) 2021-05-07 2023-11-23 ALX Oncology Inc. Exatecan derivatives and antibody-drug conjugates thereof
TW202317199A (zh) 2021-06-25 2023-05-01 大陸商同宜醫藥（蘇州）有限公司 配體藥物偶聯物及其應用
CA3224492A1 (en) 2021-07-19 2023-01-26 Xiaojun Han Immunoconjugates and methods
JP2024536798A (ja) 2021-09-23 2024-10-08 シャンハイ ハンソー バイオメディカル カンパニー リミテッド 抗体薬物コンジュゲート並びにその製造方法及び医薬用途
CN115850291B (zh) 2021-09-24 2024-11-15 石药集团巨石生物制药有限公司 喜树碱衍生物及其用途
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
KR20240142405A (ko) 2021-11-17 2024-09-30 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. 항체-약물 복합체 및 그의 용도
CN116212044A (zh) 2021-12-03 2023-06-06 成都百利多特生物药业有限责任公司 抗人Trop2抗体-喜树碱类药物偶联物及其医药用途
CN118414339A (zh) 2021-12-16 2024-07-30 迈威(上海)生物科技股份有限公司 一种喜树碱类化合物及其偶联物
MX2024008036A (es) 2021-12-28 2024-07-15 Beigene Switzerland Gmbh Conjugados de anticuerpo y farmaco.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155976A1 (ja) 2014-04-10 2015-10-15 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲート
JP2018509175A (ja) 2014-12-22 2018-04-05 システィミューン， インク．Ｓｙｓｔｉｍｍｕｎｅ， Ｉｎｃ． 二重特異性四価抗体並びにその製作及び使用方法
CN111689980A (zh) 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OGITANI, Y., et al.，"DS-8201a, a novel her2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1."，CLINICAL CANCER RESEARCH，2016年10月15日，Vol.22, No.20，pp.5097-5108，DOI: 10.1158/1078-0432.CCR-15-2822

Also Published As

Publication number Publication date
CL2024001450A1 (es) 2024-08-30
US20250115679A1 (en) 2025-04-10
CL2026000307A1 (es) 2026-03-20
US12577325B2 (en) 2026-03-17
KR20240101682A9 (ko) 2025-12-10
CN116120460B (zh) 2026-08-04
CN116120460A (zh) 2023-05-16
US20260234288A1 (en) 2026-08-13
TW202434301A (zh) 2024-09-01
EP4434548A4 (en) 2026-05-27
IL312694A (en) 2024-07-01
EP4434548A1 (en) 2024-09-25
JP2024543508A (ja) 2024-11-21
AU2022386505A1 (en) 2024-05-23
KR20240101682A (ko) 2024-07-02
US20250059296A1 (en) 2025-02-20
CA3237844A1 (en) 2023-05-19
WO2023083381A1 (zh) 2023-05-19
MX2024005831A (es) 2024-07-09
CO2024006160A2 (es) 2024-08-08
PE20250759A1 (es) 2025-03-13
JP2026035591A (ja) 2026-03-04

Similar Documents

Publication Publication Date Title
JP7686677B2 (ja) 高安定性の親水性結合ユニットを有するカンプトテシン類薬物及びその複合体
JP2026035591A (ja) 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用
WO2022078279A1 (zh) 抗体-药物偶联物及其应用
KR20220156974A (ko) 타일란스타틴 유사체
JP2024541681A (ja) 抗ヒトｔｒｏｐ２抗体－カンプトテシン薬複合体及びその医学的使用
JP7667870B2 (ja) Ｄｎａ毒性二量体及びその複合体
HK40094423A (zh) 双特异性抗体-喜树碱类药物偶联物及其医药用途
TW202532076A (zh) 抗claudin18.2抗體-喜樹鹼藥物偶聯物及其醫藥用途
TW202604572A (zh) 抗人ｄｌｌ３抗體–喜樹鹼衍生物偶聯物及其醫藥用途
HK40094591A (en) Anti-human trop2 antibody-camptothecin drug conjugate and medical use thereof
HK40116345A (en) Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
TW202546005A (zh) 抗體-奧瑞他汀藥物偶聯物以及其製造及使用方法
WO2026030396A1 (en) Anti-human ror1 antibody-drug conjugate and uses thereof
JP2025533577A (ja) 抗ｃｄ３３抗体及び抗ｃｄ３３抗体－薬物複合体ならびにその使用
JP2025532285A (ja) 高安定性親水性リンカーユニットを有するアウリスタチン系薬物及びその複合体
CN120285217A (zh) 双特异性抗体-奥瑞他汀类药物偶联物及其用途
JP2026502348A (ja) Ａｄｃコンジュゲーションのためのトポイソメラーゼｉ阻害剤のプロドラッグおよびその使用方法
TW202600598A (zh) 免疫綴合物及其製藥用途
HK40117561A (en) Anti-human trop2 antibody-camptothecin drug conjugate and medical use thereof

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250409

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251029

R150 Certificate of patent or registration of utility model

Ref document number: 7767613

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150